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Purpose: The Finnish Genetics of Pre-eclampsia
Consortium (FINNPEC) Study was established to set up
a nationwide clinical and DNA database on women
with and without pre-eclampsia (PE), including their
partners and infants, in order to identify genetic risk
factors for PE.
Participants: FINNPEC is a cross-sectional case–
control cohort collected from 5 university hospitals in
Finland during 2008–2011. A total of 1450 patients
with PE and 1065 pregnant control women without PE
(aged 18–47 years) were recruited. Altogether, there
were 1377 full triads (625 PE and 752 control triads).
Findings to date: The established cohort holds both
clinical and genetic information of mother–infant–father
triads representing a valuable resource for studying the
pathogenesis of the disease. Furthermore, maternal
biological samples (first and third trimester serum and
placenta) will provide additional information for PE
research. Until now, research has encompassed studies
on candidate genes, Sanger and next-generation
sequencing, and various studies on the placenta.
FINNPEC has also participated in the InterPregGen
study, which is the largest investigation on maternal
and fetal genetic factors underlying PE until now.
Future plans: Ongoing studies focus on elucidating
the role of immunogenetic and metabolic factors in PE.
Data on morbidity and mortality will be collected from
mothers and fathers through links to the nationwide
health registers.
INTRODUCTION
Pre-eclampsia (PE) is a complex vascular
pregnancy disorder. PE begins with a placen-
tal trigger followed by a maternal systemic
response. The condition is heterogeneous in
origin, which results in considerable variation
in the clinical presentation.1 Its classical clin-
ical features are maternal hypertension and
proteinuria developing after the 20th week
of gestation. The rest of the systemic features
can vary from mild cases with little systemic
involvement to multiorgan failure.2 This has
often led to inconsistent results in attempts
to understand PE on the basis of a single
pathogenetic hypothesis.
PE is the leading cause of maternal and
neonatal morbidity and mortality and affects
2–8% of pregnancies worldwide, with a
higher prevalence in developing countries.3 4
The aetiology of PE remains largely
unknown, but immunological and angio-
genic factors are known to play a role in the
development of the disease.5 6 Placentation
in early pregnancy appears to involve speciﬁc
maternal immune responses to fetal alloanti-
gens.7 In addition, an imbalance of proan-
giogenic and antiangiogenic factors has been
demonstrated, speciﬁcally increased levels of
the antiangiogenic soluble fms-like tyrosine
kinase 1, and reduced levels of proangio-
genic placental growth factor.8 These
changes appear in the circulation before
clinical signs are apparent; thus, measuring
circulating angiogenic proteins may serve as
a diagnostic and screening tool for PE.
Epidemiological studies over the past ﬁve
decades have provided robust and consistent
support for the clinical observation that PE
Strengths and limitations of this study
▪ The established cohort holds both clinical and
genetic information of mother–infant–father
triads representing a resource for studying the
pathogenesis of pre-eclampsia (PE).
▪ Maternal biological samples (first and third tri-
mester serum and placenta) provide a possibility
for further PE research.
▪ A major strength of this study is its large multi-
centre prospective design with opportunities for
follow-up through linking to the national data
sources as well as the recalling of participants
for future studies.
▪ The Finnish Genetics of Pre-eclampsia
Consortium (FINNPEC) cohort also includes
valuable information on socioeconomic position
such as educational attainment and occupational
status.
▪ Women with PE in this cohort have been referred
to university hospitals, and thus may represent
the more severe end of the disease.
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runs in families.9–11 Deciphering the genetic involve-
ment in PE is challenging, not least because the pheno-
type is expressed only in pregnant women.12 Moreover,
it is necessary to consider two genotypes, that of the
mother and that of the fetus which includes genes inher-
ited from the mother and father. After almost two
decades of molecular research, no genetic variants have
been reproducibly associated with PE. Genome-wide
linkage studies of PE have revealed a number of mater-
nal susceptibility loci; however, they have not been inde-
pendently replicated.13 14 Moreover, a large number of
candidate genes have been tested addressing mainly the
maternal genotype and the susceptibility loci therein
but, in common with the experience in other complex
disorders, these have generated inconsistent results.13 15 16
The identiﬁcation of genetic variants demands large
DNA collections from affected mothers and babies,
and also controls with reliable supporting phenotypic
data.11
PE is also known to have consequences for the long-
term health of the mother and her child. In particular, a
linkage of the pathophysiology of PE and later cardiome-
tabolic disease has been suggested by large epidemio-
logical studies, but is not well substantiated at a
mechanistic level.17
The Finnish Genetics of Pre-eclampsia Consortium
(FINNPEC) is a cross-sectional case–control cohort col-
lected from the ﬁve university hospitals in Finland
during 2008–2011. It was established to set up a nation-
wide clinical and DNA database on women with and
without PE, including their partners and infants in
order to identify genetic risk factors for PE. The study
represents a prospective cohort design with detailed clin-
ical outcome information allowing to characterise accur-
ately the subphenotypes of PE. This study will also
provide the opportunity to analyse combined clinical
and genetic data. Biobank samples from the ﬁrst and
third trimesters provide a resource for further preg-
nancy research.
COHORT DESCRIPTION
Altogether, 1450 patients with PE and 1065 pregnant
control women without PE were recruited at the ﬁve
Finnish university hospitals. There were altogether 1377
full triads (625 PE and 752 control triads), the number
of available samples and information is presented in
table 1.
There are two arms of the study. In the prospectively
recruited arm, PE women (n=923) and women with
normal pregnancies (n=1009) were identiﬁed on admis-
sion at all university hospitals in Finland (Helsinki,
Kuopio, Oulu, Tampere and Turku). The baby and the
spouse of each participant (father of the child) were
also enrolled for the study (table 1 and ﬁgure 1). After
the recruitment of a PE woman, a woman with a non-PE
pregnancy attending the same clinic was recruited as a
control woman. In the retrospectively recruited arm of
the study, all women who had been diagnosed with PE
or placental insufﬁciency during their pregnancies were
retrospectively identiﬁed based on medical records of
the hospitals and invited to participate (from years
2000–2008, except in Kuopio University Hospital which
recruited from years 1990–2008). These women were
ﬁrst contacted by letter by a physician in the hospital
where they were diagnosed and treated for the disorder.
Altogether, 583 women participated in the retrospective
study, but 56 of them did not fulﬁl the diagnostic criteria
for PE and were included as controls. All participants
provided written informed consent.
Inclusion criteria
Nulliparous or multiparous women with a singleton
pregnancy were eligible for the study. PE was deﬁned as
hypertension and proteinuria occurring after 20 weeks
gestation according to the American College of
Obstetricians and Gynecologists (ACOG) 2002 criteria.18
Hypertension was deﬁned as systolic blood pressure
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg.
Proteinuria was deﬁned as the urinary excretion of
Table 1 Number of available samples (November 2015)
Pre-eclampsia (n=1450) Control (n=1065)
Mother Father Baby Mother Father Baby
Serum 1 Trimester 267 282
Serum 3 Trimester 277 243
Antepartum 150 42
At delivery 35 24
Postpartum 92 177
DNA P: 879 P: 677 P: 859 P: 922 771 972
R: 525 R: 55
Cord blood 805 878
Cord plasma 486 526
Placental tissue, 9-site 101 78
Background information P: 749 P: 616 P: 780 P: 701
R: 494 R: 52
P, prospective study arm; R, retrospective study arm (only maternal DNA was collected).
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≥0.3 g protein in a 24-hour specimen, or 0.3 g/L, or two
≥1+ readings on a dipstick in a random urine determin-
ation with no evidence of a urinary tract infection. The
control group included pregnant women who suffered
from proteinuria without hypertension (n=19) and
women who suffered from gestational hypertension but
did not meet the criteria for PE (n=111 and n=28 for
the prospective and retrospective arms, respectively).
Haemolysis, elevated liver enzymes and low platelet
count (HELLP) syndrome was diagnosed when at least
two of the following criteria were met: lactate dehydro-
genase ≥235 U/L, alanine aminotransferase ≥70 U/L,
aspartate aminotransferase ≥70 U/L, thrombocytes
≤100 E9/L. Each diagnosis was ascertained based on
hospital records and conﬁrmed independently by a
research nurse and a study physician.
Exclusion criteria
Exclusion criteria were multiple pregnancy, maternal
age <18 years and the inability to provide an informed
consent based on information in Finnish or Swedish.
Background, obstetric and perinatal data
Extensive information on medical history, family history,
obstetric history, pregnancy complications, pregnancy
outcome, proteinuria, blood pressure, laboratory mea-
surements, delivery and newborn was obtained from the
hospital records (∼500 variables).
The participating mother and father were also asked
to ﬁll in a detailed questionnaire on background infor-
mation. The questionnaire included data on pre-
pregnancy weight and height, pregnancy history includ-
ing previous PE and family history of PE, personal
medical history, family medical history and lifestyle
factors (physical activity, smoking and diet). Data on pre-
pregnancy weight, height, diastolic and systolic blood
pressure at ﬁrst antenatal visit, and smoking status were
also obtained from primary care maternity records. A
woman was considered as a pre-pregnancy smoker if she
still smoked 6 months before conception.
PE was deﬁned as early onset when delivery occurred
before 34+0 weeks of gestation and late onset when at
34+0 weeks of gestation or later. Preterm delivery was
deﬁned as delivery occurring before 37 weeks of gesta-
tion. Birth weights below −2.0 SD units were classiﬁed as
small-for-gestational age (SGA) according to Finnish
standards.19
Socioeconomic factors
The participating mother and father were asked to ﬁll in
a detailed questionnaire on socioeconomic factors
including education, occupation and marital status.
Biological samples
A venous blood sample was drawn from mothers and
fathers (table 1). Genomic DNA was extracted from
Figure 1 Flow chart of the FINNPEC Study. FINNPEC, Finnish Genetics of Pre-eclampsia Consortium. IUGR, intrauterine
growth restriction.
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whole blood using the NucleoSpin Blood XL DNA
extraction kit (Macherey-Nagel GmbH and Co) or
Chemagic Magnetic Separation Module I-machine
(Chemagen) and subsequently stored at −20°C.
First and third trimester serum samples were collected
from a subcohort from the Hospital District of Helsinki
and Uusimaa only. First trimester serum samples were
obtained via ﬁrst trimester biochemical screening for
fetal chromosome abnormalities (range 9–15 weeks of
gestation), and third trimester (range 20–42 weeks of
gestation) serum samples were collected at hospitals at
recruitment. Table 1 shows the number of antepartum,
at delivery and postpartum samples for the third trimes-
ter. All samples drawn before contractions were regarded
as antepartum samples.
Cord blood, cord plasma and placental samples were
collected after delivery from a subcohort. The placental
samples were collected according to a nine-site protocol
where the placenta is divided into nine sections and a
biopsy sample is harvested from each of these sections.
The samples were obtained shortly after detachment of
the placenta: 70% of the samples were collected within
half an hour, 92.5% within an hour and the remaining
three samples within 80 min of placental detachment.
The samples were subsequently stored in an RNA later
solution at −80°C.
Basic characteristics
PE women were older and suffered more from obesity
and pre-existing medical conditions (eg, chronic hyper-
tension, type 1 diabetes and gestational diabetes) com-
pared with control women (table 2). The proportion of
primiparous women was also higher in the PE group
(table 2). In women who later developed PE, both dia-
stolic and systolic blood pressure were already increased
at the ﬁrst antenatal visit occurring on average at 8.6
±1.5 weeks of gestation. In women suffering from PE,
proteinuria occurred on average at 34.7±3.9 weeks of
gestation. Proteinuria was also observed in some controls
but they did not meet the diagnostic criteria for PE.
There were no differences in age, body mass index
(BMI) or self-reported chronic hypertension between
the fathers in the PE and control groups (table 2).
Altogether, 262 of the 1450 PE pregnancies (18.1%)
were early onset (delivery before 34+0 weeks of gesta-
tion). The women in the early-onset group were older
and they had had more pregnancies and deliveries than
mothers in the late-onset group (table 3). Furthermore,
they had more proteinuria and higher diastolic blood
pressure already at the ﬁrst antenatal visit. They also suf-
fered more frequently from chronic hypertension.
There were no differences in smoking before or during
pregnancy. These ﬁndings support the view that classify-
ing PE into early-onset and late-onset disease differenti-
ates two distinct clinical forms with pathophysiologically
speciﬁc features.
Women with PE more often reported a history of PE
(14.8% in women with PE vs 1.7% in controls). These
data were based on hospital records and/or question-
naires. The possibility for recall bias must be acknowl-
edged. More detailed information will be published in
the near future after information on PE history has
been veriﬁed solely from the hospital records.
In the FINNPEC Study, controls were more often
smokers before and during pregnancy than women with
PE. We also detected a trend for greater proportion of
SGA babies for those women with PE who smoked
during pregnancy (data not shown).
FINDINGS UNTIL NOW
The established cohort holds both clinical and genetic
information of mother–infant–father triads representing
a resource for studying the pathogenesis of the disease
as well as later implications in the mother, father and
the offspring. Furthermore, placental samples collected
will provide an important addition for future research.
The research so far from the FINNPEC has encom-
passed studies on candidate genes (heme oxygenase-1
promoter and CYP subfamily 2J polypeptide 2),20 21
Sanger and next-generation sequencing22 23 and various
studies on the placenta.24 25 FINNPEC has also served as
a replication cohort in various collaborative efforts to
identify genetic risk factors for PE.15 26
Ongoing studies focus on elucidating the role of
immunogenetic and metabolic factors in PE.
Metabolomic studies on serum samples collected at the
ﬁrst and third pregnancy trimesters, respectively, and on
fetal cord plasma will be performed in collaboration
with researchers from the University of Eastern Finland.
Family study
The Finnish Pre-eclampsia Family Study14 27 will be
expanded by families with PE recruited from the
FINNPEC cohort. Those participants who have reported
in the background information questionnaire having
ﬁrst-degree relatives with a history of PE will be
requested to contact their relatives and provide them
with oral or written information about the FINNPEC
Study and the research group’s contact information with
the support of an information letter. First-degree and
second-degree relatives (parents, siblings, grandparents,
uncles, aunts and cousins) of the study participants will
be recruited. The protocol for collecting the families
with PE has already been approved by the Ethics
Committee.
Long-term follow-up
PE is known to have consequences for the long-term
health of the mother and child.17 There are very little
long-term data on the morbidity and mortality of
fathers. Thus, data on morbidity and mortality (focusing
on cardiometabolic disease) will be collected from
mothers and fathers through links to the nationwide
health registers including the Hospital Discharge
Register with data on hospital inpatient and outpatient
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care and Cause-of-Death Register in collaboration with
the National Institute for Health and Welfare (THL)
and Statistics Finland. Furthermore, data on familial PE
history data will be collected through linkage to these
registers. Linkage to health registers is possible through
the Finnish personal identiﬁcation numbers.
International collaboration
FINNPEC has participated in the genetic studies of PE
in Central Asian and European populations
(InterPregGen), which was the largest investigation on
the maternal and fetal genetic factors underlying PE
until now (http://www.interpreggen.org).28 It was
funded by the European Community’s Seventh
Framework Programme. Six hundred PE women, 600
affected fetuses and 600 healthy pregnant control
women from the FINNPEC cohort were included in the
follow-up genotyping after the genome-wide association
screening was performed in the discovery cohorts.
FINNPEC also participates in the Global Pregnancy
Table 2 Maternal, perinatal and paternal characteristics of pre-eclamptic and control groups in FINNPEC





Age at delivery, year 30.3±5.5 (1449) 29.8±5.2 0.015
Gravity 1.9±1.6 2.3±1.7 <0.001
Parity 0.5±1.1 0.8±1.3 <0.001
Primiparous 1065 (73.5%) 596 (56.0%) <0.001
Weight, kg (self-reported, pre-pregnancy) 68.8±15.1 (1447) 66.3±13.0 (1064) <0.001 <0.001‡
Height, m 1.65±0.06 (1449) 1.66±0.06 (1064) 0.001
BMI, kg/m2 (self-reported, pre-pregnancy)§ 25.3±5.2 (1447) 24.1±4.4 (1063) <0.001 <0.001‡
Systolic blood pressure at first antenatal visit, mm Hg 125±13 (1407) 119±13 (1023) <0.001 <0.001¶
Diastolic blood pressure at first antenatal visit, mm Hg 78±10 (1407) 73±10 (1023) <0.001 <0.001¶
Highest systolic blood pressure, mm Hg** 167±19 131±17 (1063) <0.001 <0.001¶
Highest diastolic blood pressure, mm Hg 110±9 87±11 (1063) <0.001 <0.001¶
Proteinuria (maximum), g/24 hour 4.2±4.1 (1283) –
Smoking before pregnancy 313 (22.2%) (1396) 288 (27.4%)
(1037)
0.003
Smoking during pregnancy 108 (7.6%) (1404) 121 (11.5%)
(1052)
0.005
Chronic hypertension†† 259 (17.9%) 65 (6.1%) <0.001
Gestational hypertension‡‡ – 139 (13.1%) –
Gestational diabetes mellitus 207 (14.3%) 89 (8.4%) <0.001
Pregestational diabetes mellitus 47 (3.2%) 9 (0.8%) <0.001
Type 1 diabetes 38 (2.6%) 6 (0.6%) <0.001
Type 2 diabetes 9 (0.6%) 3 (0.3%) 0.223
Mode of delivery
Vaginal 757 (52.3%) 889 (83.5%)
Caesarean section 693 (47.8%) 175 (16.4%)
Birth weight, g 2692±897 3455±687 <0.001 <0.001§§
Relative birth weight, SD −1.0±1.3 (1449) −0.2±1.1 <0.001 <0.001§§
SGA 306 (21.1%) 71 (6.7%) <0.001
Gestational weeks 36.4±3.5 39.3±2.3 <0.001 <0.001‡
Paternal characteristics
Age, years 32.5±6.3 (699) 32.3±5.9 (854) 0.478
BMI, kg/m2 (self-reported) 26.2±3.9 (548) 26.1±3.5 (611) 0.568
Chronic hypertension (requiring medication,
self-reported)
14 (2.6%) (545) 9 (1.5%) (616) 0.176
()Number of available information/samples unless from all.
Data are presented as mean±SD or percentages.
Bold text shows p values <0.05.
*Unadjusted.
†Adjusted.
‡Adjusted for parity, mother’s age at birth.
§Based on weight and height before pregnancy, self-reported at first antenatal visit.
¶Adjusted for parity, mother’s age at birth, pre-pregnancy BMI.
**When highest diastolic value recorded.
††Systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg detected before 20 weeks of gestation.
‡‡Blood pressure ≥140/90, no proteinuria.
§§Adjusted for parity, mother’s age at birth, gestation weeks, pre-pregnancy BMI, chronic hypertension, gestational diabetes, pregestational
diabetes mellitus.
BMI, body mass index; FINNPEC, Finnish Genetics of Pre-eclampsia Consortium; SGA, small-for-gestational age.
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Table 3 Early-onset (delivery before 34 +0 weeks of gestation) versus late-onset pre-eclampsia
Maternal or perinatal characteristics
Pre-eclampsia











Age, year 31.5±6.1 (261) 30.0±5.3 29.8±5.2 <0.001 <0.001 0.239
Gravity 2.3±2.0 1.9±1.5 2.3±1.7 0.014 0.934 <0.001
Primiparous 176 (67.2%) 889 (74.8%) (1187) 596 (56.0%) 0.013 0.001 <0.001
Weight, kg (self-reported, pre-pregnancy) 68.9±14.6 (261) 68.8±15.2 (1186) 66.3±13.0 (1064) 0.713* 0.006* <0.001*
BMI, kg/m2 (self-reported, pre-pregnancy) 25.6±5.1 (261) 25.2±5.3 (1186) 24.1±4.4 (1063) 0.542* <0.001* <0.001*
Systolic blood pressure at first antenatal visit, mm Hg 126±14 (256) 124±13 (1151) 119±13 (1023) 0.160† <0.001† <0.001†
Diastolic blood pressure at first antenatal visit, mm Hg 80±10 (256) 77±10 (1151) 73±10 (1023) 0.001† <0.001† <0.001†
Highest systolic blood pressure, mm Hg 177±19 165±18 131±17 (1063) <0.001† <0.001† <0.001†
Highest diastolic blood pressure, mm Hg 115±10 109±9 87±11 (1063) <0.001† <0.001† <0.001†
Proteinuria (maximum), g/24 hours 6.7±5.4 (254) 3.6±3.4 (1029) <0.001†
Smoking before pregnancy 43 (17.1%) (251) 270 (23.4%) (1145) 288 (27.4%) (1037) 0.058 0.001 0.041
Smoking during pregnancy 26 (10.3%) (251) 82 (7.1%) (1153) 121 (11.5%) (1052) 0.200 0.875 0.001
Chronic hypertension 71 (27.1%) 188 (15.8%) 65 (6.1%) <0.001 <0.001 <0.001
Gestational diabetes mellitus (diet and/or insulin treated) 29 (11.1%) 178 (15.0%) 89 (8.4%) 0.096 0.173 <0.001
Pregestational diabetes mellitus 5 (1.9%) 42 (3.5%) 9 (0.8%) 0.175 0.133 <0.001
Birth weight, g 1307±423 2997±652 3455±687 <0.001‡ <0.001‡ <0.001‡
SGA 135 (51.3%) 171 (14.4%) (1185) 71 (6.7%) <0.001 <0.001 <0.001
Relative birth weight (SD) −2.0±1.0 −0.8±1.2 −0.2±1.1 <0.001‡ <0.001‡ <0.001‡
Gestation weeks 30.3±2.4 37.7±1.9 39.3±2.3 <0.001* <0.001* <0.001*
Bold text shows p values <0.05.
*Adjusted for parity, mother’s age at birth.
†Adjusted for parity, mother’s age at birth, pre-pregnancy BMI.
‡Adjusted for parity, mother’s age at birth, pre-pregnancy BMI, chronic hypertension, gestational diabetes, pregestational diabetes mellitus.


















Collaboration (CoLab), a major Bill and Melinda Gates
Foundation supported initiative focused on adverse
pregnancy outcomes and achieving a better understand-
ing of their causes.29 CoLab is the largest international
initiative until now to understand major pregnancy dis-
orders in a global setting.
STRENGTHS AND LIMITATIONS
A major strength of this study is its large multicentre
prospective design with opportunities for follow-ups as
well as the recalling of participants for future studies.
The established cohort holds both clinical and genetic
information of mother–infant–father triads representing
a resource for studying the pathogenesis of PE.
Furthermore, maternal biological samples (ﬁrst and
third trimester serum and placenta) will provide add-
itional information for PE research.
In addition, one of the strengths of the current study
is the ascertainment of the outcome: each diagnosis was
ascertained based on hospital records and conﬁrmed
independently by a research nurse and a study phys-
ician. When rediagnosed carefully using this protocol,
not all recruited cases meet the criteria for PE. Most of
these women suffered from gestational hypertension
without proteinuria.
The majority of genetic studies of PE have until now
focused on maternal genetic contribution. However, owing
to the placental origin of PE, it is likely that fetal and/or
paternal genetic factors play a central role in the pathogen-
esis. Evidence supports the idea that paternal and/or fetal
genetic factors might contribute to the risk of PE.30 31 It
has been shown that men born to a PE pregnancy are
twice as likely to father a PE pregnancy.30 In addition, men
who have fathered a PE pregnancy are nearly twice as
likely to father a PE pregnancy with a different woman.31
Thus, it is important to include the father and the off-
spring in genetic studies of PE. The study design at
FINNPEC opens up this possibility for detecting maternal,
paternal and fetal genes and their interactions.
Association between PE and the development of
maternal cardiovascular diseases (CVDs) later in life has
been well established through epidemiological
research.17 Follow-up studies that will be carried out in
FINNPEC through linkage of the national data sources
may help identify prognostic subgroups of mothers,
fathers and infants that have a linkage between PE and
later life CVD and other non-communicable diseases. In
future, this may provide tools for early screening and tar-
geted postpartum preventive strategies.
The FINNPEC cohort also includes information on
socioeconomic position such as educational attainment
and occupational status, which are currently being ana-
lysed. This is important because the role of socioeconomic
position as a risk factor of PE has been little studied.
It must be acknowledged that a large unselected
material would have had more epidemiological advan-
tages. This cohort is not directly generalisable to the
general population since the participants represented a
Finnish population of women with PE who were referred
to university hospitals and thus may represent a more
severe end of the disease. However, apart from serving
as a tertiary centre of a larger catchment area, all these
hospitals serve as primary delivery hospitals for a smaller
catchment area. The incidence of early-onset disease
(18.1%) was comparable to reports in population-based
studies,32 whereas the incidence of HELLP (7.4%) was
quite high. However, the most severe cases are missing
as deliveries had taken place immediately before recruit-
ment could take place.
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